Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

Home > Press > Spectrum Pharmaceuticals acquires Renazorb(TM) and Renalan(TM) from Altair Nanotechnologies

Abstract:
Spectrum Pharmaceuticals, Inc. has acquired all the patent rights associated with Renazorb(TM) and Renalan(TM) from Altair Nanotechnologies, Inc., a manufacturer of nanomaterials and nano-based products. Spectrum Pharmaceuticals is a biotechnology company focused on Oncology. Both the companies are based in the US.

Spectrum Pharmaceuticals acquires Renazorb(TM) and Renalan(TM) from Altair Nanotechnologies

Irvine, CA | Posted on August 10th, 2009

This agreement amends and restates an existing, limited licensing agreement between Spectrum and Altair, for Renazorb(TM) and Renalan(TM) compound. Spectrum will now have exclusive worldwide rights to Renazorb(TM), Renalan(TM), and any related compounds in any field of use.

Under terms of the agreement, Altair would receive $0.75 million in Spectrum restricted common stock. In addition to the royalty and other payments, Altair was to receive under the prior license agreement. Altair would now receive 10% of any fees Spectrum may receive from the sub-licensing of Renazorb(TM), Renalan(TM), and any related compounds.

Update on June 7, 2006:

Altair announced it would receive 0.1 million shares of Spectrum stock for a milestone payment and an additional 0.04 million shares for product development improvements, with a total approximate value of $0.55 million, following a mutually agreed upon resolution to arbitration proceedings involving the two companies. Altair and Spectrum would continue efforts to move the RenaZorb product technology to market quickly.

Announcement (January 31, 2005):

Spectrum has acquired worldwide exclusive rights to RenaZorb (two second-generation lanthanum-based phosphate binding agents) from Altair. These novel non-aluminum, non-calcium phosphate binders which utilize Altair' proprietary lanthanum nanomaterial technology have the potential to treat hyperphosphatemia, in patients with end-stage renal disease and chronic kidney disease.

Under the terms of the agreement, Spectrum acquired an exclusive worldwide license to develop and commercialize RenaZorb(TM) for all human therapeutic and diagnostic uses. In return, Spectrum would pay to Altair an upfront payment of 0.1 million shares of restricted Spectrum common stock and would make an equity investment of $0.2 million for 38,314 shares of Altair common stock. In addition, Altair would be eligible to receive payments upon achievement of a clinical development and certain regulatory and sales milestones, in addition to royalties on potential net sales.

####

About Spectrum Pharmaceuticals
Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI), is a biopharmaceutical company that acquires, develops and commercializes a diversified portfolio of oncology and other drug candidates that meet critical health challenges for which there are few other treatment options. The Company’s pipeline includes promising early and late-stage drug candidates with unique formulations and mechanisms of action that address the needs of seriously ill patients, such as at-home chemotherapy and new treatment regimens for refractory disease.

For more information, please click here

Contacts:
Spectrum Pharmaceuticals, Inc.
157 Technology Drive
Irvine, CA 92618
Phone: (949) 788-6700
Fax: (949) 788-6706

Copyright © tradingmarkets.com

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related Links

Spectrum Pharmaceuticals

Related News Press

News and information

Quantum twisted Loong confirms the physical reality of wavefunctions September 23rd, 2017

Application of air-sensitive semiconductors in nanoelectronics: 2-D semiconductor gallium selenide in encapsulated nanoelectronic devices September 22nd, 2017

Researchers set time limit for ultrafast perovskite solar cells September 22nd, 2017

DNA triggers shape-shifting in hydrogels, opening a new way to make 'soft robots' September 21st, 2017

Investments/IPO's/Splits

Arrowhead Hosts Investor & Analyst R&D Day to Introduce TRiM(TM) Platform and Lead RNAi-based Drug Candidates September 14th, 2017

Nanometrics Announces Upcoming Investor Events August 3rd, 2017

Nanometrics to Participate in the 9th Annual CEO Investor Summit 2017: Accredited investor and publishing research analyst event held concurrently with SEMICON West and Intersolar 2017 in San Francisco June 27th, 2017

180 Degree Capital Corp. Announces the Start of Kevin Rendino as Chairman and Chief Executive Officer and Completion of its Transition to a Registered Closed-End Fund March 31st, 2017

Nanomedicine

Do titanium dioxide particles from orthopedic implants disrupt bone repair? September 16th, 2017

Arrowhead Hosts Investor & Analyst R&D Day to Introduce TRiM(TM) Platform and Lead RNAi-based Drug Candidates September 14th, 2017

Graphene based terahertz absorbers: Printable graphene inks enable ultrafast lasers in the terahertz range September 13th, 2017

Applications for the nanomedTAB are open until September 18th, 2017 September 13th, 2017

Announcements

Quantum twisted Loong confirms the physical reality of wavefunctions September 23rd, 2017

Application of air-sensitive semiconductors in nanoelectronics: 2-D semiconductor gallium selenide in encapsulated nanoelectronic devices September 22nd, 2017

Researchers set time limit for ultrafast perovskite solar cells September 22nd, 2017

DNA triggers shape-shifting in hydrogels, opening a new way to make 'soft robots' September 21st, 2017

Patents/IP/Tech Transfer/Licensing

Nanoparticles limit damage in spinal cord injury: Injection after an injury reduces inflammation and scarring September 6th, 2017

More durable, less expensive fuel cells: University of Delaware researchers have developed a new technology that could speed up the commercialization of fuel cell vehicles September 5th, 2017

Argonne National Laboratory’s Continuous ALD Technology Licensed Exclusively to Forge Nano July 7th, 2017

Aculon Expands NanoProof® Product Line for Electronics Waterproofing Technology: With growing market opportunities Aculon Launches NanoProof® 8 with Push Through Connectivity™ and NanoProof® DAB a syringe application May 30th, 2017

Nanobiotechnology

DNA triggers shape-shifting in hydrogels, opening a new way to make 'soft robots' September 21st, 2017

Do titanium dioxide particles from orthopedic implants disrupt bone repair? September 16th, 2017

Applications for the nanomedTAB are open until September 18th, 2017 September 13th, 2017

Magnetic cellular 'Legos' for the regenerative medicine of the future September 12th, 2017

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project